PFE RSI Chart
Last 7 days
0.4%
Last 30 days
9.8%
Last 90 days
3.4%
Trailing 12 Months
-22.4%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 57.8B | 0 | 0 | 0 |
2023 | 32.7B | 33.0B | 23.6B | 46.5B |
2022 | 49.9B | 34.2B | 32.8B | 32.6B |
2021 | 46.1B | 55.1B | 68.9B | 60.9B |
2020 | 37.9B | 34.5B | 32.1B | 41.7B |
2019 | 41.0B | 40.8B | 40.2B | 40.9B |
2018 | 52.7B | 53.2B | 53.4B | 40.8B |
2017 | 52.6B | 52.3B | 52.5B | 52.5B |
2016 | 51.0B | 52.3B | 53.2B | 52.8B |
2015 | 49.1B | 48.2B | 47.9B | 48.9B |
2014 | 50.5B | 50.3B | 50.0B | 49.6B |
2013 | 52.7B | 51.7B | 51.4B | 51.6B |
2012 | 59.7B | 57.1B | 53.5B | 55.2B |
2011 | 65.1B | 64.4B | 65.1B | 61.3B |
2010 | 55.0B | 61.1B | 65.5B | 65.2B |
2009 | 47.3B | 46.2B | 45.8B | 49.3B |
2008 | 0 | 48.4B | 48.3B | 48.3B |
2007 | 0 | 0 | 0 | 48.4B |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index
Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.
Returns of $10,000 invested in:
Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022
Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 28, 2024 | boshoff christoffel | sold (taxes) | -112,216 | 27.04 | -4,150 | executive vice president |
Feb 28, 2024 | dolsten mikael | sold (taxes) | -579,656 | 27.04 | -21,437 | president r&d |
Feb 28, 2024 | boshoff christoffel | acquired | - | - | 11,510 | executive vice president |
Feb 27, 2024 | damico jennifer b. | acquired | - | - | 5,113 | svp & controller |
Feb 27, 2024 | de germay alexandre | acquired | - | - | 74,377 | executive vice president |
Feb 26, 2024 | mcdermott michael | sold (taxes) | -164,792 | 27.18 | -6,063 | executive vice president |
Feb 25, 2024 | boshoff christoffel | sold (taxes) | -172,029 | 27.76 | -6,197 | executive vice president |
Feb 25, 2024 | boshoff christoffel | acquired | - | - | 15,455 | executive vice president |
Feb 25, 2024 | mcdermott michael | sold (taxes) | -83,057 | 27.76 | -2,992 | executive vice president |
Feb 25, 2024 | damico jennifer b. | sold (taxes) | -38,475 | 27.76 | -1,386 | svp & controller |
Which funds bought or sold PFE recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 17, 2024 | Plato Investment Management Ltd | added | 1,716 | 3,480,640 | 3,691,500 | 0.38% |
May 17, 2024 | VIMA LLC | added | 100 | 10,562 | 16,320 | 0.01% |
May 17, 2024 | Aspect Partners, LLC | added | 12.36 | 1,450 | 18,926 | 0.01% |
May 17, 2024 | CITIZENS FINANCIAL GROUP INC/RI | reduced | -16.06 | -802,239 | 3,400,210 | 0.11% |
May 17, 2024 | Heartland Bank & Trust Co | sold off | -100 | -399,029 | - | -% |
May 17, 2024 | New Covenant Trust Company, N.A. | new | - | 220,363 | 220,363 | 0.22% |
May 17, 2024 | Investmark Advisory Group LLC | added | 73.09 | 976,066 | 2,436,380 | 1.34% |
May 17, 2024 | Advisory Resource Group | sold off | -100 | -206,675 | - | -% |
May 17, 2024 | Kozak & Associates, Inc. | added | 1.5 | 622 | 17,639 | -% |
May 17, 2024 | Lummis Asset Management, LP | sold off | -100 | -325,730 | - | -% |
Unveiling Pfizer Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Pfizer Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 364.2B | 85.6B | 9.47 | 4.25 | ||||
MRK | 331.8B | 61.4B | 143.88 | 5.4 | ||||
AMGN | 168.8B | 29.5B | 44.85 | 5.71 | ||||
PFE | 161.7B | 57.8B | 129.02 | 2.8 | ||||
GILD | 84.6B | 27.4B | 174.6 | 3.08 | ||||
TEVA | 19.0B | 16.0B | -38.5 | 1.19 | ||||
MID-CAP | ||||||||
ALKS | 4.1B | 1.7B | 9.5 | 2.39 | ||||
PRGO | 4.0B | 4.6B | -522.97 | 0.88 | ||||
BHC | 2.4B | 9.0B | -5.24 | 0.27 | ||||
AMPH | 2.1B | 676.2M | 13.62 | 3.11 | ||||
SMALL-CAP | ||||||||
TLRY | 1.5B | 743.2M | -4.24 | 2.01 | ||||
TXMD | 24.7M | 1.3M | -3.33 | 18.96 | ||||
ACRX | 18.4M | 89.6M | -1.29 | 0.19 | ||||
AGRX | 2.4M | 21.5M | -0.31 | 0.11 | ||||
ACOR | 757.7K | 115.7M | 0 | 0.01 |
Pfizer Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -43.2% | 14,879 | 26,198 | 13,232 | 3,490 | 3,627 | 3,261 | 22,638 | 3,219 | 3,526 | 3,420 | 24,035 | 18,899 | 14,516 | 11,427 | 10,277 | 9,864 | 10,083 | 1,843 | 12,680 | 13,264 | 13,118 |
S&GA Expenses | -23.6% | 3,495 | 4,575 | 3,281 | 3,497 | 3,418 | 4,645 | 3,391 | 3,048 | 2,593 | 4,104 | 2,899 | 2,923 | 2,777 | 3,739 | 2,658 | 2,659 | 2,541 | 2,616 | 3,260 | 3,511 | 3,339 |
EBITDA Margin | -41.4% | 0.12* | 0.21* | 0.76* | 0.91* | 1.17* | 1.26* | 1.22* | 1.13* | 0.69* | 0.51* | 0.43* | 0.40* | - | - | - | - | - | - | - | - | - |
Interest Expenses | -60.9% | 415 | 1,062 | 332 | 402 | 419 | 321 | 350 | 318 | 453 | 262 | 407 | 353 | 445 | 344 | 387 | 438 | 472 | 341 | 437 | 424 | 385 |
Income Taxes | 136.9% | 293 | -795 | -964 | -71.00 | 715 | 230 | 356 | 1,570 | 1,172 | 249 | -328 | 1,123 | 808 | -64.00 | -347 | 422 | 359 | -1,982 | 3,047 | -915 | 433 |
Earnings Before Taxes | 182.9% | 3,421 | -4,129 | -3,352 | 2,269 | 6,270 | 5,231 | 9,001 | 11,447 | 9,050 | 3,827 | 7,843 | 6,949 | 5,692 | 598 | 570 | 3,026 | 2,842 | -7,869 | 10,727 | 4,141 | 4,323 |
EBT Margin | -236.3% | -0.03* | 0.02* | 0.44* | 0.69* | 0.98* | 1.06* | 1.02* | 0.94* | 0.55* | 0.40* | 0.31* | 0.25* | - | - | - | - | - | - | - | - | - |
Net Income | 2149.1% | 3,115 | 139 | -2,382 | 382 | 473 | 211 | 8,608 | 210 | 468 | 578 | 8,146 | 330 | 461 | 221 | 1,469 | 518 | 405 | 37.00 | 148 | 5,046 | 3,884 |
Net Income Margin | 172.7% | 0.02* | -0.03* | -0.06* | 0.29* | 0.29* | 0.29* | 0.30* | 0.27* | 0.19* | 0.16* | 0.13* | 0.05* | - | - | - | - | - | - | - | - | - |
Free Cashflow | -90.8% | 386 | 4,196 | 2,646 | -2,122 | 73.00 | 7,581 | 5,133 | 7,419 | 5,898 | 4,912 | 10,211 | 10,762 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -2.4% | 221,000 | 226,501 | 42,830 | 220,168 | 196,000 | 197,000 | 41,137 | 195,290 | 183,841 | 181,476 | 46,335 | 169,920 | 158,818 | 154,229 | 44,975 | 44,244 | 45,840 | 167,594 | 46,081 | 156,199 | 155,000 |
Current Assets | -2.1% | 42,415 | 43,333 | 5,876 | 73,347 | 50,078 | 51,259 | 5,932 | 67,466 | 54,420 | 59,693 | 6,890 | 48,814 | 39,533 | 35,067 | 6,614 | 7,136 | 8,213 | 32,803 | 7,505 | 47,073 | 45,290 |
Cash Equivalents | -72.7% | 780 | 2,853 | 3,148 | 2,632 | 2,166 | 416 | 1,338 | 1,824 | 2,513 | 1,983 | 2,034 | 2,418 | 1,809 | 1,825 | 1,627 | 1,845 | 2,196 | 1,350 | 2,846 | 1,837 | 2,018 |
Inventory | 6.9% | 10,892 | 10,189 | 10,204 | 10,310 | 9,541 | 8,981 | 9,513 | 10,454 | 9,979 | 9,059 | 8,640 | 8,948 | 8,493 | 8,020 | 9,295 | 8,564 | 8,423 | 7,068 | 8,222 | 8,233 | 8,029 |
Net PPE | -0.7% | 18,803 | 18,940 | 17,862 | 17,488 | 17,052 | 16,274 | 15,441 | 15,244 | 15,109 | 14,882 | 14,436 | 14,224 | 14,011 | 13,745 | 14,403 | 14,113 | 14,040 | 12,969 | 13,701 | 13,521 | 13,467 |
Goodwill | 2.2% | 69,297 | 67,783 | 51,527 | 51,572 | 51,476 | 51,375 | 823 | 49,891 | 50,211 | 49,208 | 49,489 | 49,867 | 49,791 | 49,556 | 59,902 | 58,449 | 58,502 | 48,181 | 58,665 | 53,352 | 53,487 |
Liabilities | -6.3% | 128,537 | 137,213 | 21,862 | 120,875 | 94,381 | 101,288 | 22,455 | 107,821 | 101,155 | 104,013 | 10,351 | 99,605 | 89,953 | 90,756 | 10,576 | 10,187 | 10,677 | 104,148 | 10,776 | 96,274 | 96,263 |
Current Liabilities | -15.3% | 40,497 | 47,794 | 6,117 | 34,647 | 36,562 | 42,138 | 5,235 | 47,410 | 39,268 | 42,671 | 5,133 | 35,664 | 26,652 | 25,920 | 5,246 | 4,992 | 5,524 | 37,304 | 5,241 | 32,030 | 29,423 |
Long Term Debt | -1.1% | 61,307 | 62,000 | 61,048 | 61,356 | 31,704 | 32,884 | 32,629 | 34,294 | 35,656 | 36,000 | 36,250 | 35,354 | 35,347 | 37,000 | 49,785 | 50,529 | 36,281 | 35,955 | 36,044 | 36,168 | 35,733 |
LT Debt, Current | -55.6% | 1,001 | 2,254 | 2,260 | 3,565 | 3,567 | 2,560 | 2,566 | 1,276 | 260 | 1,636 | 2,663 | 3,687 | 3,676 | 2,002 | 2,149 | 1,481 | 337 | 1,462 | 2,431 | 2,139 | 4,471 |
LT Debt, Non Current | -100.0% | - | 62,000 | 61,048 | 61,356 | 31,704 | 32,884 | 32,629 | 34,294 | 35,656 | 36,000 | 36,250 | 35,354 | 35,347 | 37,000 | 49,785 | 50,529 | 36,281 | 35,955 | 36,044 | 36,168 | 35,733 |
Shareholder's Equity | 4.0% | 92,558 | 89,014 | 20,719 | 99,293 | 101,236 | 95,661 | 18,455 | 87,469 | 82,685 | 77,462 | 35,705 | 70,315 | 68,865 | 63,473 | 34,154 | 64,570 | 65,341 | 63,447 | 35,199 | 59,924 | 59,158 |
Retained Earnings | 2.5% | 121,318 | 118,353 | 126,411 | 128,796 | 131,102 | 125,656 | 122,967 | 116,608 | 111,193 | 103,394 | 102,252 | 96,346 | 95,158 | 90,392 | 100,284 | 100,203 | 101,000 | 97,670 | 100,113 | 94,440 | 93,388 |
Additional Paid-In Capital | 0.4% | 92,997 | 92,631 | 92,496 | 92,329 | 92,153 | 91,802 | 91,359 | 91,183 | 90,844 | 90,591 | 89,973 | 89,336 | 89,002 | 88,674 | 88,161 | 87,886 | 87,680 | 87,428 | 87,099 | 86,963 | 86,635 |
Accumulated Depreciation | 2.0% | 16,362 | 16,045 | 15,779 | 15,554 | 15,514 | 15,174 | 14,931 | 14,969 | 15,358 | 15,074 | 15,403 | 15,328 | 15,105 | 14,812 | 16,636 | 16,889 | 16,929 | 16,789 | 16,728 | 16,389 | 16,158 |
Shares Outstanding | 0.2% | 5,657 | 5,643 | 5,646 | 5,640 | 5,634 | 5,608 | 5,606 | 5,605 | 5,617 | 5,601 | 5,597 | 5,598 | - | - | - | - | - | - | - | - | - |
Minority Interest | 0.7% | 276 | 274 | 249 | 274 | 266 | 256 | 227 | 261 | 261 | 262 | 279 | 273 | 245 | 235 | 245 | 138 | 133 | 303 | 105 | 357 | 352 |
Float | - | - | - | - | 207,000 | - | - | - | 294,000 | - | - | - | 223,000 | - | - | - | 169,000 | - | - | - | 241,000 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -79.2% | 1,090 | 5,240 | 3,456 | -1,208 | 1,212 | 8,582 | 5,974 | 8,170 | 6,541 | 5,914 | 10,829 | 11,299 | 4,538 | 5,625 | 2,090 | 3,555 | 3,133 | 3,769 | 4,510 | 2,611 | 1,698 |
Share Based Compensation | 81.8% | 220 | 121 | 151 | 148 | 105 | 364 | 135 | 287 | 86.00 | 496 | 293 | 221 | 172 | 287 | 224 | 187 | 57.00 | 239 | 64.00 | 199 | 185 |
Cashflow From Investing | 115.8% | 1,732 | -10,996 | 888 | -25,485 | 3,315 | -4,410 | -627 | -11,313 | 567 | -2,586 | -10,076 | -8,137 | -1,747 | 8,330 | 481 | -13,011 | -71.00 | -2,833 | -6,760 | -1,902 | 7,550 |
Cashflow From Financing | -190.6% | -4,931 | 5,442 | -3,779 | 27,174 | -2,771 | -5,015 | -5,761 | 2,520 | -6,578 | -3,351 | -1,101 | -2,557 | -2,807 | -13,787 | -2,821 | 9,159 | -2,200 | -2,440 | 3,273 | -851 | -8,467 |
Buy Backs | - | - | - | - | - | - | - | - | - | 2,000 | - | - | - | - | - | - | - | - | - | - | - | 8,865 |
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | |||||||
---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | Apr. 02, 2023 | |||||||
Alliance revenues | [1] | $ 2,172 | $ 2,060 | |||||
Total revenues | 14,879 | 18,486 | ||||||
Costs and expenses: | ||||||||
Cost of sales | [2] | 3,379 | 4,886 | |||||
Selling, informational and administrative expenses | [2] | 3,495 | 3,418 | |||||
Research and development expenses | [2] | 2,493 | 2,505 | |||||
Acquired in-process research and development expenses | 0 | 21 | ||||||
Amortization of intangible assets | 1,308 | 1,103 | ||||||
Restructuring charges and certain acquisition-related costs | 102 | 9 | ||||||
Other (income)/deductions––net | 680 | 275 | ||||||
Income from continuing operations before provision/(benefit) for taxes on income | [3] | 3,421 | 6,270 | |||||
Provision/(benefit) for taxes on income | 293 | 715 | ||||||
Income from continuing operations | 3,128 | 5,555 | ||||||
Discontinued operations––net of tax | (5) | 1 | ||||||
Net income before allocation to noncontrolling interests | 3,123 | 5,556 | ||||||
Less: Net income attributable to noncontrolling interests | 8 | 13 | ||||||
Net income attributable to Pfizer Inc. common shareholders | $ 3,115 | $ 5,543 | ||||||
Earnings per common share––basic: | ||||||||
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) | $ 0.55 | $ 0.98 | ||||||
Discontinued operations––net of tax (in dollars per share) | 0 | 0 | ||||||
Net income attributable to Pfizer Inc. common shareholders (in dollars per share) | 0.55 | 0.98 | ||||||
Earnings per common share––diluted: | ||||||||
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) | 0.55 | 0.97 | ||||||
Discontinued operations––net of tax (in dollars per share) | 0 | 0 | ||||||
Net income attributable to Pfizer Inc. common shareholders (in dollars per share) | $ 0.55 | $ 0.97 | ||||||
Weighted-average shares--basic (in shares) | 5,657 | 5,634 | ||||||
Weighted-average shares--diluted (in shares) | 5,697 | 5,727 | ||||||
Product revenues | ||||||||
Revenues | [1] | $ 12,443 | $ 16,221 | |||||
Royalty revenues | ||||||||
Revenues | [1] | $ 263 | $ 204 | |||||
|
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions | Mar. 31, 2024 | Dec. 31, 2023 | ||||||
---|---|---|---|---|---|---|---|---|
Assets | ||||||||
Cash and cash equivalents | $ 719 | $ 2,853 | ||||||
Short-term investments | 11,209 | 9,837 | ||||||
Trade accounts receivable, less allowance for doubtful accounts: 2024—$479; 2023—$470 | 10,989 | 11,566 | ||||||
Inventories | [1] | 10,892 | 10,189 | |||||
Current tax assets | 4,233 | 3,978 | ||||||
Other current assets | 4,372 | 4,911 | ||||||
Total current assets | 42,415 | 43,333 | ||||||
Equity-method investments | 8,123 | 11,637 | ||||||
Long-term investments | 3,490 | 3,731 | ||||||
Property, plant and equipment, less accumulated depreciation: 2024—$16,362; 2023—$16,045 | 18,803 | 18,940 | ||||||
Identifiable intangible assets | [2] | 62,829 | 64,900 | |||||
Goodwill | [3] | 69,297 | 67,783 | |||||
Noncurrent deferred tax assets and other noncurrent tax assets | 4,942 | 3,706 | ||||||
Other noncurrent assets | 11,197 | 12,471 | ||||||
Total assets | 221,095 | 226,501 | ||||||
Liabilities and Equity | ||||||||
Short-term borrowings, including current portion of long-term debt: 2024—$1,001; 2023—$2,254 | 8,232 | 10,350 | ||||||
Trade accounts payable | 5,591 | 6,710 | ||||||
Dividends payable | 0 | 2,372 | ||||||
Income taxes payable | 3,192 | 2,349 | ||||||
Accrued compensation and related items | 2,192 | 2,776 | ||||||
Deferred revenues | 2,502 | 2,700 | ||||||
Other current liabilities | 18,788 | 20,537 | ||||||
Total current liabilities | 40,497 | 47,794 | ||||||
Long-term debt | 61,307 | 61,538 | ||||||
Pension and postretirement benefit obligations | 2,076 | 2,167 | ||||||
Noncurrent deferred tax liabilities | 931 | 640 | ||||||
Other taxes payable | 8,603 | 8,534 | ||||||
Other noncurrent liabilities | 15,122 | 16,539 | ||||||
Total liabilities | 128,537 | 137,213 | ||||||
Commitments and Contingencies | ||||||||
Common stock | 480 | 478 | ||||||
Additional paid-in capital | 92,997 | 92,631 | ||||||
Treasury stock | (114,755) | (114,487) | ||||||
Retained earnings | 121,318 | 118,353 | ||||||
Accumulated other comprehensive loss | (7,758) | (7,961) | ||||||
Total Pfizer Inc. shareholders’ equity | 92,282 | 89,014 | ||||||
Equity attributable to noncontrolling interests | 276 | 274 | ||||||
Total equity | 92,558 | 89,288 | ||||||
Total liabilities and equity | $ 221,095 | $ 226,501 | ||||||
|
Dr. Albert Bourla D.V.M., DVM, Ph.D. | |
pfizer.com | |
Pharmaceuticals | |
65535 |